Molbio Diagnostics Eyes ₹200 Crore IPO for Expansion Amid Growth

Molbio Diagnostics, a leading player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aimed at raising ₹200 crore to bolster its capital expenditures. The company also plans to reduce its promoter stake by securing an additional ₹740 crore through an offer for sale. This strategic move will see the promoter group's stake decrease from 46.6% to 43%.

Founded in 2000, Molbio has established itself in the diagnostics industry with a focus on both infectious and non-communicable diseases. It operates six manufacturing facilities across India and serves a diverse clientele in over 90 countries. Notably, government health programs and international aid agencies contribute significantly to its revenue, accounting for over 80% of its income.

Strong Revenue Growth Driven by Tuberculosis Test Kits

The company has reported substantial financial growth, particularly from its tuberculosis diagnostic test kits. Between FY24 and FY26, Molbio's revenue from operations grew by 31.5% annually, reaching ₹1,445.7 crore. During the same period, net profit saw a 40.2% annual increase, amounting to ₹164.1 crore. The company’s EBITDA also rose by 33.2% to ₹328.2 crore, with an improved EBITDA margin of 22.6% in FY26, up from 22% in FY24.

Molbio's flagship product, the 'Truenat' platform, is a portable diagnostic system designed for resource-limited settings, providing rapid and accurate test results within an hour. The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays and extends its services through subsidiaries and strategic collaborations.

Market Position and Valuation

Despite the lack of directly comparable listed peers in India, Molbio's financial metrics are competitive with other healthcare diagnostics and medical device companies. These companies, such as Poly Medicure and Dr. Lal PathLabs, exhibit P/E multiples ranging from 54 to 81. Molbio's post-IPO valuation demands a P/E multiple of up to 57, reflecting its market position and growth prospects.

The company's reliance on a few key clients, who contribute over half of its revenue, highlights a concentration risk. Nonetheless, its robust growth trajectory and innovative diagnostic solutions offer attractive prospects for investors willing to embrace higher risk for potential long-term gains.

Molbio's strategic focus on expanding its manufacturing capabilities and reducing promoter stakes aligns with its broader vision of enhancing operational efficiency and shareholder value. As the company continues to innovate and expand its global footprint, the IPO represents a significant step towards achieving its growth ambitions.